Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03343093 · ClinicalTrials.gov registry record · NA
Restore: Improving Sexual Outcomes of Gay and Bisexual Prostate Cancer Survivors
A NA study of Prostatic Neoplasm, sponsored by University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 403
- Enrollment target
- 1
- Study location
NCT03343093: Completed NA study of Prostatic Neoplasm, sponsored by University of Minnesota.
NCT03343093 is a NA study of Prostatic Neoplasm that has completed, run by University of Minnesota. The registered enrollment target is 403 participants, above the 208-participant average among 9 other Prostatic Neoplasm trials with a reported enrollment target (94% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03343093, a NA study of Prostatic Neoplasm, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 403 participants
- Enrollment target
- 1
- Study location
Study Summary
Development and evaluation of an online intervention addressing sexual functioning in gay and bisexual men (GBM) after prostate cancer treatment.
Primary Outcome
The Urinary Function domain of the Expanded Prostate Cancer Index Composite (EPIC-50) scale was used to assess the frequency of urinary symptoms. Scores range from 0 to 100, with higher scores indicating less frequency of urinary symptoms.
Conditions Studied
Interventions
- BEHAVIORAL Control
- BEHAVIORAL Restore Rehabilitation Program
Study Locations (1)
Minnesota
- University of Minnesota Twin Cities Campus - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 403 participants |
| Start Date | 2019-01-01 |
| Est. Completion | 2023-06-20 |
| Phase | NA |
What the finished NCT03343093 record still lists
NCT03343093 is an interventional study that assigns participants to a tested intervention. The registered 403 participants enrollment target is mid-sized for trials with a published cap, above the 208-participant average among 9 other Prostatic Neoplasm trials with a reported enrollment target (94% higher).
The record links to 1 condition, with Prostatic Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Control is the first listed.
NCT03343093 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03343093 about?
NCT03343093 is a clinical study titled "Restore: Improving Sexual Outcomes of Gay and Bisexual Prostate Cancer Survivors". Development and evaluation of an online intervention addressing sexual functioning in gay and bisexual men (GBM) after prostate cancer treatment.
What is the current status of trial NCT03343093?
This trial is currently completed. It is a NA study. The enrollment target is 403 participants. The study started on 2019-01-01. Estimated completion is 2023-06-20.
What conditions does trial NCT03343093 study?
This clinical trial studies the following conditions: Prostatic Neoplasm.
What interventions are being tested in trial NCT03343093?
The interventions under investigation include: Control (BEHAVIORAL), Restore Rehabilitation Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT03343093?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03343093 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03343093's enrollment target sits among peer trials
403 2nd of 9 the highest of 9 other Prostatic Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostatic Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Investigation of Impact of AI on Prostate Cancer Workflow
RECRUITING · NA
-
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors
COMPLETED · NA
-
Prostate Cancer Genetic Risk Evaluation and Screening Study
RECRUITING
-
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
ACTIVE NOT RECRUITING · Phase 2
-
Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness
ACTIVE NOT RECRUITING · Phase 1
-
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05647122 · 403 participants · Phase 1
First in Human Study of AZD9592 in Solid Tumors
- NCT05674799 · 403 participants · NA
NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks
- NCT06244771 · 403 participants · Phase 1
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- NCT05049057 · 404 participants · Phase 2
Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI